UnitedHealth Group signage is displayed on a monitor on the floor of the New York Stock Exchange.
Michael Nagle | Bloomberg | Getty Images
UnitedHealth shares fell more than 6% on Wednesdayafterthe UK’sGuardian newspaper reported that the company made secret payments to nursing homes to reduce hospital transfers, adding to the woes of the healthcare conglomerate.
The alleged action, part of a series of cost-cutting tactics, has saved the company millions, but at times risked residents’ health, the Guardian reported, citing an investigation.
The allegations add to the litany of negatives that have hurtUnitedHealthin the last several months, following a massive cyberattack at its Change Healthcare unit, reports of criminal and civil investigations into the company’s practices, including one for Medicare fraud and the abrupt departure of CEO Andrew Witty last week.
Shares have stumbled all year, losing more than 39%, compared with a 0.6% decrease for the Dow.
UnitedHealthsaid in response that “the U.S. Department of Justice investigated these allegations, interviewed witnesses, and obtained thousands of documents that demonstrated the significant factual inaccuracies in the allegations.”
The company also said in an emailed statement that the DOJ declined to pursue the matter after reviewing all the evidence during its multi-year investigation.
Reuters has not independently verified the article’s allegations.
“The news is only seemingly getting worse forUnitedHealth,” said Sahak Manuelian, managing director, global equity trading at Wedbush.
“This is kind of a tough situation for investors to come in and have any kind of confidence in putting money to work, so we’ll have to kind of wait and see how this plays itself out, unfortunately,” Manuelian said.
Separately, HSBC downgraded the stock to “reduce” from “hold,” and cut the price target to a street-low of $270.
The brokerage said higher medical costs, pressure on drug pricing and its pharmacy benefit management unit, OptumRx, and a potential Medicaid funding cut can upset the company’s recovery journey.
The company is now counting on the experience of Stephen Hemsley, who returned as CEO to steer it through the current crisis.
“We believe Hemsley has the experience and leadership attributes that the company needs to restore credibility and right the ship,” said James Harlow, senior vice president at Novare Capital Management.